Printer Friendly

India,United States : WOCKHARDT secures Final Approval for ANTI-DEPRESSANT DRUG WELLBUTRIN SR.

Wockhardt announced that it has secured final approval from the US FDA for marketing 100 mg, 150 mg and 200 mg 12-hour extended release tablets of Bupropion HCl which is used in the treatment of depression.

Bupropion, the generic name for the brand Wellbutrin SR is marketed in the US by Glaxo Smithkline.

The product will be launched by Wockhardt soon.

The extended release tablets of Bupropion 12-Hr will be manufactured by Wockhardt at its facility in Waluj, India.

About $268 million is the total market for this product in the US, noted IMS Health.

Dr Habil Khorakiwala, Founder Chairman and Group CEO, Wockhardt added, This is our sixth ANDA approval in past two weeks and Bupropion SR 12-Hr is yet another product based on extended-release technology. Extended Release technology is a core competency of Wockhardt s R&D and they have consistently risen to the challenge of developing these technically challenging products.

2012 Al Bawaba (

Provided by an company
COPYRIGHT 2012 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Sep 5, 2012
Previous Article:India : Tech Mahindra acquires Hutchison Global Services.
Next Article:India : Tata Motors partners with J&K Bank for car financing.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters